Galderma Launches Twyneo in the US
Galderma has launched Twyneo (tretinoin and benzoyl peroxide) Cream, 0.1%/3% in the US. The launch takes place during the annual meeting of the American Academy of Dermatology (AAD) Annual Meeting. Twyneo Cream features patented microencapsulation technology that allows the delivery of two ingredients that have not been previously combined and enables their controlled release. It is the first and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne.
“Effective prescription acne treatments currently involve multi-step regimens because there is rarely a single treatment option that addresses the multiple causes of the skin condition. These routines can often result in low adherence, especially among boys,” says Caroline Robinson, MD, FAAD, Founder of Tone Dermatology. “TWYNEO Cream may help teens with acne—especially the boys—struggling with generic tretinoin or adhering to complex treatment routines, since it's a once-daily, potent combination that can be used any time of day.”
In clinical trials, some people saw results in as little as two weeks of using Twyneo Cream, and their skin continued to clear over time. These studies demonstrated a 25 percent decrease in pimples at two weeks and a 58–66 percent decrease at 12 weeks. In all, 27–41 percent of people achieved clear or almost clear skin by the end of the trial. More than half of people who used Twyneo Cream were satisfied at two weeks and by 12 weeks of treatment, 8 in 10 subjects were satisfied with their results. Twyneo Cream was well tolerated and side effects were mild to moderate and decreased over time. The most common side effects occurring in >2% of persons using TWYNEO Cream were application site pain, dryness, erythema (redness), and exfoliation.
“Twyneo Cream is a novel and exciting medical advance because its microencapsulation technology enables the combination of BPO with the highest concentration of tretinoin available. While these two treatments can be difficult to tolerate in high concentrations, Twyneo Cream was well tolerated,” says Hillary Baldwin, MD, Medical Director of Acne Treatment & Research Center and principal investigator for the Twyneo Cream clinical trials. “The patented microencapsulation technology in Twyneo Cream segregates and envelopes the active ingredients in silica core shells that keep both crystals separate and stable while gradually releasing onto the skin.”
“As a regimen in a bottle that combines two of the most trusted first-line treatments for acne, Twyneo Cream is truly a breakthrough for teens and their parents looking for an acne treatment that fits within a simple skincare routine and provides rapid, noticeable results,” says Heather Chase, Head of Rx Marketing and Customer Experience, Galderma US. " Twyneo Cream is another example of Galderma's commitment to providing cutting-edge treatments to advance dermatology for every skin story."
Twyneo Cream will be available throughout the US by prescription in Q2. A month’s supply of Twyneo Cream costs $0 for commercially covered patients or $60 for uninsured patients with the Galderma CAREConnect savings card. Twyneo Cream may cost less than generic tretinoin alone when using the Galderma CAREConnect savings card.